- Nouveau Biosciences has entered into an agreement with Ardena to manufacture its lead nanomedicine asset, Kromastat.
- The partnership supports the progression of the cancer therapeutic towards clinical development.
Nouveau Biosciences has signed an agreement with Ardena to manufacture its lead asset Kromastat, previously known as NBS-M001. The agreement is intended to support the advancement of the targeted nanomedicine into the clinic.
Under the agreement, Ardena will provide manufacturing support for Kromastat, drawing on its dedicated nanomedicine division. The company offers synthesis, conjugation and production of nanomedicines, supported by Annex 1 compliant GMP manufacturing and associated bioanalytical services as part of its CDMO and contract manufacturing activities.
Ardena’s capabilities span small molecule API manufacturing, development and accelerated manufacturing, alongside bioanalytical CRO services. The company stated that its integrated platform is designed to support the development of complex therapies, including nanomedicines, through to clinical stages.
Nouveau Biosciences is developing a proprietary drug discovery platform combined with polymer-based nanochemistry technology to improve drug targeting, tolerability and efficacy in cancer therapeutics. Kromastat is the company’s clinic-ready lead asset and forms part of a broader pipeline of targeted nanomedicines.
“This collaboration represents an extremely critical step for Nouveau, not just with our lead asset, but for our rapidly evolving pipeline as well.”
Owen A. O’Connor, Chief Executive Officer and Chairman of Nouveau Biosciences
